One of the most aggressive and incurable cancers that still sustain poor survival outcomes even with the application of modern medical achievements is pancreatic cancer. The number of those diagnosed with this disease is still frighteningly high. Researchers are reaching for variants to the traditional treatments for this disease, and the most promising of such is the re-purposing of some of the existing drugs. The candidate that came out as the most curious for people was fenbendazole, which is the antiparasitic found in veterinary medicine. The drug was first developed for animals to get rid of their intestinal parasites, but the ongoing conversations and anecdotal reports show that it can be associated with cancer treatment in humans, especially pancreatic cancer. But is it the truth or just the hype?
A Brief Analysis of Pancreatic Tumors and the Consequences
Pancreatic cancer is essentially known for its gradual progression and non-traditional reaction to standard treatments. Different from other cancers, during its early stage, pancreatic cancer is non-displaying, and a person can detect it only at the last stage, which is life-threatening. Chemotherapy and radiotherapy, besides surgeries, only show very little effect in the treatment of this disease. That is why apparent failures are steering the scientists towards alternative therapies, including the use of non-cancer drugs that might contain some overlooked anticancer properties.
What Is Fenbendazole and Why Is It in the Pipeline for Clinical Trials?
Fenbendazole is a benzimidazole-class drug, a member of which works as a dewormer for the majority of livestock and pets. It attacks the worm's feeding process, which in turn kills the worms that are parasitic in nature. The drug is designed to be mainly used on animals, yet it has the same features found in other benzimidazole compounds (for example, mebendazole and albendazole), the only difference being that these two drugs are approved for parasitic infections in humans.
The connection between fenbendazole and cancer treatment has emerged based on hearsay that the drug may perturb the function of microtubules, which are an essential structural component of the cells. Seeing that the cells can multiply in an unregulated manner is what we’re talking about when discussing cancer. It is why researchers thought that affecting microtubules, like some other chemotherapeutic agents do, might be a feasible way of stopping cancer development. Even though some early research works such as in vitro studies were shown to work, there is a lack of scientific validation to support these results so far.
Scientific Excitement and Fenbendazole-Cancer Link
On the preliminary stage, research has been made on the influence of fenbendazole on different types of cancer cells. The results showed that in a few cases, fenbendazole could be responsible for the induction of apoptosis (programmed cell death) as well as the inhibition of the uptake of glucose in cancer cells. Due to the fact that cancer cells consume a lot of glucose, this makes this treatment significant in cancer therapy.
A few researches that are related to the use of fenbendazole on lung cancer, glioblastoma, and colorectal cancer were carried out, and it was found that in some cases, the drug is effective. As of now, there is no evidence to show that fenbendazole can be used for human cancer treatment, but the small scale of the clinical trials did succeed in seeing good results. The scientific community has still been quite conservative and is recommending the controlled study principle before drawing any final conclusion.
Have We Got Any Hope for Pancreatic Cancer With Fenbendazole?
Because pancreatic cancer is notorious due to its being so aggressive, the challenges existing in treating it would be quite different from those in treating other types of cancer. The primary problem for treatment in such cases is the fact that most of them point to resistance, which makes it mandatory to take different approaches from the ordinary therapies.
If fenbendazole disrupts the way the cancer cells work, then by no time would it be an additional therapy in the treatment of pancreatic cancer. One of the main points of investigation in fenbendazole is its potential to improve the current treatments. Experimental data clearly support the notion that fenbendazole enhances cetuximab and gefitinib's cytotoxicity and thereby switches the energy metabolism in cancer cells. Besides, it is theorized that these abilities of fenbendazole to interfere with glucose metabolism in the tumor cells would provoke a weakening strategy in these cells.
In spite of the hypothetical advantages obtained through this approach, it is important to point out that no clinical trials have been carried out specifically on pancreatic cancer patients to find out what interaction there actually is between fenbendazole and pancreatic tumors. The information about this drug is far from comprehensive, and it is still speculative whether this can be used in the treatment of cancer patients.
Anecdotal Evidence and Self-Experimentation
There have been many anecdotal reports of patient self-experimentation with fenbendazole for cancer, mostly shared in online support groups. Some people claim they have been helped, but there are wide variations in the stories, and they have not been verified scientifically. While they might be convincing, the human factor in the responses to a treatment raises the necessity of conducting experiments on a variety of test subjects.
Apart from the undocumented research, questions about the safety of this practice with fenbendazole are to be raised. Its use in humans other than in animals has not been investigated with regard to its long-term consequences, so the risks remain unsolved. Dosage, toxicity, and drug-drug interactions have not been clearly determined yet, therefore very careful administration with professional medical guidance is needed.
The Issues Moving Forward and the Proposed Solutions
In the case of fenbendazole as a candidate drug for pancreatic cancer, serious investigation should be performed in clinical trials. Studies should run to put an estimate on the level of side effects, the period a drug is under work, the way it is taken, dosage, and whether it interacts with other medications. It is only through such data that a conclusion can be drawn as to whether the drug would ultimately give more advantages or if the side effects will dominate.
Also, regulatory bodies should come to a decision and agree on human applications other than what is being practiced currently. The drug for human use must undergo rigorous testing and supervision that could take some years. So, if the drug is repurposed for a different use, the time it will take would probably be longer. Until then, it remains a theoretical medical approach and has not been tested.
Final Thoughts
The proposal on the use of fenbendazole for the treatment of pancreatic cancer is very appealing, but indeed, it is a long way from being a successful cure. Early signs depicted by laboratory work and by anecdotes were the reason for speculation among the people, and now this idea is part of scientific literature.
Pancreatic cancer is a solid and multifaceted disease that makes every bit of input necessary for medicine regarding the topic to have sound and factual bases. Those interested in alternative approaches are encouraged to consult medical practitioners and avail themselves of evidence-based treatments. Research will continue to create a clearer picture in exploring treatments made from the drugs not usually employed, but the enthusiasm surrounding fenbendazole remains more of a medical research subject than a proven cancer cure.
Sign in to leave a comment.